Additional file 8 of Comprehensive analysis of alternative splicing across multiple transcriptomic cohorts reveals prognostic signatures in prostate cancer

Additional file 8: Table S8. Cox regression between our event signature and traditional clinicopathological parameters. (a) Univariate and multivariate Cox regression of the alternative splicing event signature and clinicopathological factors with respect to the biochemical recurrence-free survival of prostate cancer patients in the TCGA-PRAD training set. TCGA: The Cancer Genome Atlas; PRAD: prostate adenocarcinoma; Age: age at diagnosis; T stage: tumour stage; N stage: lymph node status (N0 = without lymph node metastasis; N1 = with lymph node metastasis). HR: hazard ratio of the parameter; HR.95L: the lower limit of 95% confidence interval; HR.95H: the upper limit of the 95% confidence interval; p: p-values obtained from the likelihood ratio test. (b) Univariate and multivariate Cox regression of the alternative splicing event signature and clinicopathological factors with respect to the biochemical recurrence-free survival of prostate cancer patients in the TCGA-PRAD testing set. TCGA: The Cancer Genome Atlas; PRAD: prostate adenocarcinoma; Age: age at diagnosis; T stage: tumour stage; N stage: lymph node status (N0 = without lymph node metastasis; N1 = with lymph node metastasis). HR: hazard ratio of the parameter; HR.95L: the lower limit of 95% confidence interval; HR.95H: the upper limit of the 95% confidence interval; p: p-values obtained from the likelihood ratio test. (c) Univariate and multivariate Cox regression of the alternative splicing event signature and clinicopathological factors with respect to the biochemical recurrence-free survival of prostate cancer patients in the TCGA-PRAD complete set. TCGA: The Cancer Genome Atlas; PRAD: prostate adenocarcinoma; Age: age at diagnosis; T stage: tumour stage; N stage: lymph node status (N0 = without lymph node metastasis; N1 = with lymph node metastasis). HR: hazard ratio of the parameter; HR.95L: the lower limit of 95% confidence interval; HR.95H: the upper limit of the 95% confidence interval; p: p-values obtained from the likelihood ratio test..

附加文件8：表S8。本研究中的可变剪接事件特征与传统临床病理参数间的Cox回归分析。
(a) 在TCGA-PRAD训练集中，针对前列腺癌患者的无生化复发生存期，对可变剪接事件特征及临床病理因素开展单因素与多因素Cox回归分析。TCGA：癌症基因组图谱（The Cancer Genome Atlas）；PRAD：前列腺腺癌（prostate adenocarcinoma）；Age：诊断时年龄；T stage：肿瘤分期；N stage：淋巴结状态（N0=无淋巴结转移；N1=伴淋巴结转移）。HR：风险比（hazard ratio）；HR.95L：95%置信区间下限；HR.95H：95%置信区间上限；p：似然比检验所得P值。
(b) 在TCGA-PRAD测试集中，针对前列腺癌患者的无生化复发生存期，对可变剪接事件特征及临床病理因素开展单因素与多因素Cox回归分析。TCGA：癌症基因组图谱（The Cancer Genome Atlas）；PRAD：前列腺腺癌（prostate adenocarcinoma）；Age：诊断时年龄；T stage：肿瘤分期；N stage：淋巴结状态（N0=无淋巴结转移；N1=伴淋巴结转移）。HR：风险比（hazard ratio）；HR.95L：95%置信区间下限；HR.95H：95%置信区间上限；p：似然比检验所得P值。
(c) 在TCGA-PRAD完整集中，针对前列腺癌患者的无生化复发生存期，对可变剪接事件特征及临床病理因素开展单因素与多因素Cox回归分析。TCGA：癌症基因组图谱（The Cancer Genome Atlas）；PRAD：前列腺腺癌（prostate adenocarcinoma）；Age：诊断时年龄；T stage：肿瘤分期；N stage：淋巴结状态（N0=无淋巴结转移；N1=伴淋巴结转移）。HR：风险比（hazard ratio）；HR.95L：95%置信区间下限；HR.95H：95%置信区间上限；p：似然比检验所得P值。